Loading...

SOHO 2026 Annual Meeting

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters

Showing 1,267 results.

Thumbnail for Effect of Ianalumab Plus Eltrombopag on Patient-Reported Outcomes in Primary Immune Thrombocytopenia: Results from the VAYHIT2 Phase 3 Trial

MDS - 435

Effect of Ianalumab Plus Eltrombopag on Patient-Reported Outcomes in Primary Immune Thrombocytopenia: Results from the VAYHIT2 Phase 3 Trial

Mary Lisha Paul

Poster Presenter: Mary Lisha Paul

Thumbnail for Improving Survival and Increasing Disease Burden in Chronic Myelomonocytic Leukemia: Population-Based Trends and Projections From SEER, 2000-2022

MDS - 456

Improving Survival and Increasing Disease Burden in Chronic Myelomonocytic Leukemia: Population-Based Trends and Projections From SEER, 2000-2022

Arjun Syal

Poster Presenter: Arjun Syal

Thumbnail for Clonal Hematopoiesis Associated With Chronic Biomass-Smoke Exposure in Indigenous Tribal Populations of Maharashtra, India: A Pilot Molecular Screening Study

MDS - 499

Clonal Hematopoiesis Associated With Chronic Biomass-Smoke Exposure in Indigenous Tribal Populations of Maharashtra, India: A Pilot Molecular Screening Study

Maitri Gada

Poster Presenter: Maitri Gada

Thumbnail for Durable Complete Remission Following HMA Therapy in Higher-Risk MDS Is Not Fully Determined by Baseline Disease Biology

MDS - 515

Durable Complete Remission Following HMA Therapy in Higher-Risk MDS Is Not Fully Determined by Baseline Disease Biology

Julie Braish

Poster Presenter: Julie Braish

Thumbnail for THE VEXUS- MDS INTERFACE: INTEGRATING MORPHOLOGICAL MARKERS AND CLONAL EVOLUTION TO PREDICT RESPONSE TO TARGETED MYELOID CELL THERAPIES

MDS - 540

THE VEXUS- MDS INTERFACE: INTEGRATING MORPHOLOGICAL MARKERS AND CLONAL EVOLUTION TO PREDICT RESPONSE TO TARGETED MYELOID CELL THERAPIES

Teshika Yalla

Poster Presenter: Teshika Yalla

Thumbnail for Hematologic Manifestations and Clonal Hematopoiesis in Telomere Biology Disorders: A Retrospective Single-Center Cohort Study

MDS - 565

Hematologic Manifestations and Clonal Hematopoiesis in Telomere Biology Disorders: A Retrospective Single-Center Cohort Study

Olisaemeka Ogbue

Poster Presenter: Olisaemeka Ogbue

Thumbnail for ATLAS: A Randomized, Double-Blind, Placebo-Controlled, Adaptive Seamless Phase 2/3 Study to Assess the Safety and Efficacy of Momelotinib in Patients With VEXAS Syndrome

MDS - 583

ATLAS: A Randomized, Double-Blind, Placebo-Controlled, Adaptive Seamless Phase 2/3 Study to Assess the Safety and Efficacy of Momelotinib in Patients With VEXAS Syndrome

Shuyan Huang

Poster Presenter: Shuyan Huang

Thumbnail for Effects of Ianalumab Treatment on B-Cell Activation, Maturation, and Maintenance of Vaccine Titers in Patients With Primary Immune Thrombocytopenia (ITP) in the Phase 2 VAYHIT3 Study

MDS - 600

Effects of Ianalumab Treatment on B-Cell Activation, Maturation, and Maintenance of Vaccine Titers in Patients With Primary Immune Thrombocytopenia (ITP) in the Phase 2 VAYHIT3 Study

Jenny Despotovic

Poster Presenter: Jenny Despotovic

Thumbnail for Treatment of higher risk Myelodysplastic Syndrome HR-MDS with high-dose chemotherapy followed by lenalidomide and azacitidine: a four-year survival update

MDS - 635

Treatment of higher risk Myelodysplastic Syndrome HR-MDS with high-dose chemotherapy followed by lenalidomide and azacitidine: a four-year survival update

Maher Salamoon

Poster Presenter: Maher Salamoon